Literature DB >> 32594103

ABO incompatibile graft management in pediatric transplantation.

Adriana Balduzzi1, Halvard Bönig2, Andrea Jarisch3, Tiago Nava4, Marc Ansari4, Alessandro Cattoni5, Giulia Prunotto5, Giovanna Lucchini6, Gergely Krivan7, Toni Matic8, Krzyzstof Kalwak9, Akif Yesilipek10, Marianne Ifversen11, Peter Svec12, Jochen Buechner13, Kim Vettenranta14, Roland Meisel15, Anita Lawitschka16, Christina Peters16, Brenda Gibson17, Arnaud Dalissier18, Selim Corbacioglu19, André Willasch3, Jean-Hugues Dalle20, Peter Bader3.   

Abstract

Up to 40% of donor-recipient pairs in SCT have some degree of ABO incompatibility, which may cause severe complications. The aim of this study was to describe available options and survey current practices by means of a questionnaire circulated within the EBMT Pediatric Diseases Working Party investigators. Major ABO incompatibility (donor's RBCs have antigens missing on the recipient's cell surface, towards which the recipient has circulating isohemagglutinins) requires most frequently an intervention in case of bone marrow grafts, as immediate or delayed hemolysis, delayed erythropoiesis and pure red cell aplasia may occur. RBC depletion from the graft (82%), recipient plasma-exchange (14%) were the most common practices, according to the survey. Graft manipulation is rarely needed in mobilized peripheral blood grafts. In case of minor incompatible grafts (donor has isohemagglutinins directed against recipient RBC antigens), isohemagglutinin depletion from the graft by plasma reduction/centrifugation may be considered, but acute tolerability of minor incompatible grafts is rarely an issue. According to the survey, minor ABO incompatibility was either managed by means of plasma removal from the graft, especially when isohemagglutinin titer was above a certain threshold, or led to no intervention at all (41%). Advantages and disadvantages of each method are discussed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32594103     DOI: 10.1038/s41409-020-0981-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies.

Authors:  Nadine Sorg; Carolin Poppe; Milica Bunos; Eva Wingenfeld; Christiane Hümmer; Ariane Krämer; Belinda Stock; Erhard Seifried; Halvard Bonig
Journal:  Transfusion       Date:  2015-02-02       Impact factor: 3.157

2.  RBC depletion from a PBSC graft.

Authors:  H Bonig; G Bug
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

3.  Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.

Authors:  Cameron Curley; Elango Pillai; Kari Mudie; Robyn Western; Cheryl Hutchins; Simon Durrant; Glen A Kennedy
Journal:  Transfusion       Date:  2011-08-16       Impact factor: 3.157

Review 4.  Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Authors:  S D Rowley; M L Donato; P Bhattacharyya
Journal:  Bone Marrow Transplant       Date:  2011-09       Impact factor: 5.483

5.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 6.  An update on ABO incompatible hematopoietic progenitor cell transplantation.

Authors:  Elizabeth M Staley; Joseph Schwartz; Huy P Pham
Journal:  Transfus Apher Sci       Date:  2016-05-11       Impact factor: 1.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.